Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Equity Average (2018 - 2025)

Sutro Biopharma's Equity Average history spans 8 years, with the latest figure at -$59.7 million for Q3 2025.

  • For Q3 2025, Equity Average fell 145.32% year-over-year to -$59.7 million; the TTM value through Sep 2025 reached -$59.7 million, down 145.32%, while the annual FY2024 figure was $97.1 million, 47.03% down from the prior year.
  • Equity Average for Q3 2025 was -$59.7 million at Sutro Biopharma, down from -$29.0 million in the prior quarter.
  • Across five years, Equity Average topped out at $319.7 million in Q1 2021 and bottomed at -$59.7 million in Q3 2025.
  • The 5-year median for Equity Average is $170.1 million (2023), against an average of $163.2 million.
  • The largest annual shift saw Equity Average soared 255.46% in 2021 before it tumbled 145.32% in 2025.
  • A 5-year view of Equity Average shows it stood at $268.1 million in 2021, then decreased by 16.67% to $223.4 million in 2022, then crashed by 41.34% to $131.0 million in 2023, then crashed by 40.54% to $77.9 million in 2024, then plummeted by 176.61% to -$59.7 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Equity Average are -$59.7 million (Q3 2025), -$29.0 million (Q2 2025), and $9.4 million (Q1 2025).